Checkrare

What Checkrare does

CheckRare, LLC is a privately-held digital content platform headquartered in New York that delivers educational programming on rare diseases to healthcare professionals, patients, and caregivers. The platform operates across a website (checkrare.com), YouTube channel, podcasts, email newsletter, and social channels (Facebook, X, Instagram, LinkedIn), organizing resources across 15-plus disease categories including congenital and genetic conditions, endocrine disorders, cancers, hematologic disorders, neurological diseases, and lysosomal storage disorders.

The core product is the CheckRare content platform, augmented by several modules: accredited CME/CE courses, expert-led podcasts, disease-specific information pages, a 2026 Orphan Drugs PDUFA and FDA Approvals tracker, a Priority Review Voucher tracker, and a rare-disease awareness calendar. Editorial output features video and written interviews with named clinicians from institutions including City of Hope, Mount Sinai, UT Southwestern, the University of Michigan, and Barts Health NHS Trust. Underlying technology is a standard content management and distribution stack — no proprietary AI/ML models, no API, no SDK, no patents, and no regulatory certifications are disclosed.

The business model rests on three revenue streams: (1) pharmaceutical-sponsored educational programs and symposia, with named sponsors including Astellas Pharma and Chiesi Pharma at WORLD*Symposium 2026; (2) advertising and promoted programs, accessed via a dedicated advertiser contact channel; and (3) CME/CE continuing-education programming, operated through a dedicated CE contact channel. Go-to-market is sales-led; customer reach is extended through mutual partnerships with patient-advocacy organizations (Congenital Hyperinsulinism International, Lipodystrophy United) and a channel relationship with specialty pharmacy Orsini Specialty Pharmacy.

Name

Checkrare

Legal name

CheckRare, LLC

Website

https://checkrare.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

CheckRare, LLC is a New York-based digital platform delivering rare-disease news, clinical insights, CME/CE courses, podcasts, and FDA-approval trackers to healthcare professionals, patients, and pharmaceutical sponsors.

Ownership category

akta.pro rank

Product category

Medical Education and Rare Disease Publishing

NAICS

Web Search Portals, Libraries, Archives, and Other Information Services (519)

akta.pro primary industry

Content Curation & Bookmarking/Read-Later Platforms (MPACAKAH)

Keywords

• Rare disease education
• Medical news platform
• Continuing medical education
• Orphan drug tracking
• Clinical insights publishing

Headquarters

HQ city

Hastings On Hudson

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Digital Commerce or Content

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Sponsored Educational Programs: Pharmaceutical companies sponsor educational symposiums and content on the platform, such as Astellas Pharma-sponsored AI in rare disease management symposium and Chiesi Pharma-sponsored Fabry disease treatment symposium.
2. Advertising / Promoted Programs: The platform generates revenue through advertising and promoted programs, with dedicated contact channels for advertisers (609.216.4356).
3. Continuing Medical Education (CME/CE): The platform offers CME/CE activities for healthcare professionals, with contact available at dedicated phone line (778.215.4160) for CE/Continuing Education inquiries.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

CheckRare operates a digital content platform that publishes rare disease news, clinical insights, expert interviews, podcasts, and CME/CE-accredited courses for healthcare professionals and patients. The platform also provides tracking resources for FDA orphan drug approvals, PDUFA dates, and priority review vouchers, with revenue generated through pharmaceutical-sponsored educational programs and advertising.

Product overview

Checkrare is a unified online educational platform for healthcare professionals and patients, providing news, clinical insights, and continuing education on rare diseases. The core platform delivers content through multiple channels including news articles, podcasts, CME/CE courses, and disease-specific information pages. Supporting resources include FDA approval tracking tools (2026 Orphan Drugs, PDUFA Dates), Priority Review Voucher tracking, and Rare Disease Awareness calendar. The platform organizes content across 15+ disease categories including Congenital And Genetic Conditions, Endocrine Disorders, Cancers, Hematologic Disorders, Lysosomal Storage Disorders, and others.

Differentiator

Problem solved

Functional benefit

Products and services

• CheckRare Platform An online and learning platform for healthcare professionals and patients providing news, insight, and clinical perspectives on rare diseases, including cutting-edge therapies, emerging technologies, and patient-centered care strategies.
• CME/CE Courses Educational programs offering continuing medical education credits for healthcare professionals covering rare disease topics, clinical trials, and treatment advances.
• Podcasts Audio content featuring expert discussions on rare disease topics, clinical insights, and patient stories.
• Disease Information Pages Comprehensive educational resources covering specific rare diseases organized by categories including Congenital And Genetic Conditions, Endocrine Disorders, Cancers, Hematologic Disorders, and more.
• 2026 Orphan Drugs: PDUFA Dates and FDA Approvals Tracking resource for FDA approval timelines and orphan drug designations for rare disease treatments.
• Priority Review Voucher Tracking Resource monitoring and analyzing priority review voucher programs for rare disease drug development.
• Rare Disease Awareness Days Recognition Calendar and resources highlighting rare disease recognition days and awareness initiatives.

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered minor.

• Congenital Hyperinsulinism InternationalminorStrategic or Co-development PartnerPatient advocacy organization providing support, research, and awareness for patients with congenital hyperinsulinism. The organization connects families with resources and global patient registry, holding family conferences twice yearly.
• Lipodystrophy UnitedminorStrategic or Co-development PartnerPatient advocacy organization (led by Executive Director Kate Stratton) focused on supporting patients with lipodystrophy, addressing mental health challenges and care gaps.
• Orsini Specialty PharmacyminorChannel Partner/ Reseller/ DistributorSpecialty pharmacy dispensing over 70 different therapies for over 50 rare conditions, offering special handling and mail order options. Featured in patient advocacy content discussing hypoparathyroidism management.

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• BioSpace: Biopharma industry news and career platform covering drug pipelines including orphan/rare disease programs; an adjacent content incumbent competing for the same life-sciences professional audience and sponsor dollars.
• Doximity: Physician network with news feed, CME, and sponsored editorial/content products; not rare-disease-specialized but competes for the same HCP attention and pharma-sponsored educational inventory.
• Healio: SLACK Inc.'s specialty medical news and education network covering endocrinology, hematology, oncology, neurology, etc., including rare disease content; competes head-to-head for HCP readership and pharma sponsorship dollars in the same disease verticals CheckRare covers.
• Endpoints News: Biopharma industry news outlet with deep rare/orphan drug and FDA-approval coverage; targets a similar HCP/biopharma readership and competes for sponsor attention on drug-development content.
• Medscape: WebMD-owned flagship HCP education, news, and CME platform covering all specialties including rare diseases; far larger and broader than CheckRare, with overlapping pharma-sponsored CME and disease-content revenue streams.
• MedPage Today: Medical news and CME provider for physicians across specialties, with breaking FDA, clinical trial, and policy coverage; a broader HCP content incumbent with overlapping pharma-sponsored and CME revenue mechanics.

Direct peers

• National Organization for Rare Disorders (NORD): Patient advocacy organization that also publishes educational content, disease-specific resources, FDA/regulatory updates, and CME-style programming for the rare-disease community; comparable in audience and content mix.
• Orphanet: Reference portal/encyclopedia for rare diseases covering thousands of conditions with clinical descriptions, treatment guidelines, and expert resources; serves the same HCP and patient audience seeking authoritative rare-disease information.
• Rare Disease Advisor (MJH Life Sciences): Most direct competitor: also a digital educational content platform dedicated to rare diseases for HCPs, with news, clinical insights, expert interviews, CME/CE, and pharma-sponsored programs. Operates under the same sponsored-content and CME revenue model as CheckRare.

Emerging players

• Rare Disease Diversity Coalition / Rare Disease News Network: Smaller rare-disease-focused content and advocacy publishers operating similar news, education, and community resources for patients/families and HCPs; partial overlap with CheckRare's vertical and content mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CheckRare
• YouTubeyoutube.com/@checkrare2738
• Facebookfacebook.com/CheckRare
• LinkedInlinkedin.com/company/checkrare
• Instagraminstagram.com/check.rare

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Checkrare